Gilead

Xos Bolsters Leadership Team with Two New Vice President Hires

Retrieved on: 
Wednesday, August 30, 2023
Lordstown Motors, Gibson, Quality, Gilead, Kia, XOS, Supply, Tesla, Renewable energy, Caterpillar

LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) a leading manufacturer of fully electric, medium- and heavy-duty commercial vehicles, powertrain components, and charging infrastructure, are pleased to announce two new vice president hires to lead the teams of their Byrdstown, TN manufacturing facility.

Key Points: 
  • LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) a leading manufacturer of fully electric, medium- and heavy-duty commercial vehicles, powertrain components, and charging infrastructure, are pleased to announce two new vice president hires to lead the teams of their Byrdstown, TN manufacturing facility.
  • The company took over the flex manufacturing site as a full in-house facility as part of Xos' goal to deliver gross margin positive units by the end of the third quarter 2023.
  • “We are thrilled to have Eric and Paul join us at this critical juncture," said Giordano Sordoni, COO & Co-Founder of Xos.
  • In his role with Xos' manufacturing team, he will ensure each vehicle meets key quality standards before leaving the facility.

Arcutis Appoints Interim Chief Financial Officer (CFO)

Retrieved on: 
Friday, August 18, 2023
IPO, Biotechnology, Unity, Allergan, Dermatitis, Unity Biotechnology, Psoriasis, Gilead, Dermatology, CFO, Growth, Kite Pharma, Therapy, Skin, Management, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer (CFO) from 2019 to 2021, has been appointed interim CFO effective August 31.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer (CFO) from 2019 to 2021, has been appointed interim CFO effective August 31.
  • “We are delighted that John has agreed to step in as interim CFO.
  • He brings an incredible depth and breadth of both financial acumen and dermatology experience from his 25+-year career in the pharmaceutical industry, culminating in five successive CFO roles including his previous stint at Arcutis,” said Frank Watanabe, President and Chief Executive Officer of Arcutis.
  • “On behalf of our Board and team, I would like to thank Scott for his tremendous contributions to Arcutis.

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, August 10, 2023
KRAS, Prostate-specific antigen, Gilead Sciences, CPI, HIV, Roche, Immune tolerance, Cancer, Arenavirus, Research, Lung, Trial of the century, Gilead, ASCO, Development, State Administrative Expenses, Investigational New Drug, American Society of Clinical Oncology, Patient, Administration, Annual general meeting, PAP, Growth, Security (finance), Pembrolizumab, IND, Society, PSA, Safety, Prostate cancer, Pharmaceutical industry, Vaccine, Clothing

NEW YORK and VIENNA, Austria, Aug. 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.

Key Points: 
  • NEW YORK and VIENNA, Austria, Aug. 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.
  • In June, HOOKIPA presented a trial-in-progress presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on its ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
  • HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
  • Preclinical studies have demonstrated the ability of HOOKIPA’s arenaviral technology to break tolerance and elicit a strong immune response against self-antigens.

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, August 9, 2023
KRAS, Chemistry, Congress, Lance, Patient, SLATE, Collaboration, Infection, Maintenance, Monitoring, Vaccination, Gritstone bio, Immunity, Research, Melinda French Gates, Gilead, ECCMID, CORAL, NCI, Vaccine, DNA, AACR, COVID-19, African, Cancer, NAB, Immunotherapy, Messenger, Government, Friends, National Cancer Institute, Bill & Melinda Gates Foundation, European, NIAID, Partnership, Circulating tumor DNA, Drug development, CRC, HIV, CMC, Clinical trial, Nature Communications, PCV, Cryptocurrency, Pharmaceutical industry, Neoplasm, Gritstone

EMERYVILLE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Molecular response, or reduction in ctDNA, is the primary efficacy endpoint for the Phase 2 portion of the GRANITE trial.
  • Gritstone delivered multiple presentations detailing advances in neoantigen prediction capabilities and cancer vaccine programs at the 2023 American Association for Cancer Research (AACR 2023, in April 2023).
  • Gritstone expects to initiate a randomized Phase 2 clinical trial within SLATE (“off-the-shelf” neoantigen vaccine program) in 2024.
  • Gritstone expects to share additional data from the CORAL-CEPI and CORAL-BOOST studies in Fall 2023.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, Net, Pressure, University, Civil service commission, Astellas Pharma, Chronic lymphocytic leukemia, Vertex, Calendar, Aplastic anemia, DPP, GAAP, Leuprorelin, Sale, Ulcerative colitis, Psoriasis, Gilead, EBITDA, Acquisition, European Commission, Patient, Risk, Metastasis, Cystic fibrosis, Growth, Johnson & Johnson, California Miramar University, FDA, Sacituzumab govitecan, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Ivacaftor, Pfizer, Talazoparib, Bank, Video game, Music, Vaccine, Pharmaceutical industry, Real estate, Cryptocurrency, Berotralstat, Apalutamide, Nusinersen, Elexacaftor/tezacaftor/ivacaftor, Adjustment, Guselkumab, Ibrutinib

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.

Galapagos announces first half-year 2023 financial results

Retrieved on: 
Thursday, August 3, 2023
Exercise, Filgotinib, RA, CET, CD19, JAK, CTA, SLE, Burn, Gilead, UC, Patient, Multiple myeloma, TYK2, Hematology, Drug discovery, Growth, IND, Arthritis, BCMA, Cryptocurrency, Pharmaceutical industry

R&D expenditure in the first six months of 2023 amounted to €211.9 million, compared to €249.5 million for the first six months of 2022.

Key Points: 
  • R&D expenditure in the first six months of 2023 amounted to €211.9 million, compared to €249.5 million for the first six months of 2022.
  • Net financial income in the first six months of 2023 amounted to €30.6 million, compared to net financial income of €67.7 million for the first six months of 2022.
  • Current financial investments and cash and cash equivalents totaled €3,874.9 million on 30 June 2023, as compared to €4,094.1 million on 31 December 2022.
  • Galapagos’ financial report for the first six months ended 30 June 2023, including details of the unaudited consolidated results, is accessible on the financial reports section of our website .

COGNIZANT REPORTS SECOND QUARTER 2023 RESULTS

Retrieved on: 
Wednesday, August 2, 2023
Cloud, Change management, Cognizant, Share repurchase, CCI, GAAP, SAP, IPA, SAP S/4HANA, Investment, Transport, HFS, ISG, Secunet Security Networks, Nuance Communications, Friends, Mount Everest, Gilead, Star, DAX, Growth, Hospitality, AT&T, Gilead Sciences, AT, Aquaculture, Google Cloud Platform, Performance, Carbon, Climate change, Google Cloud, Assessment, Payment card industry, Ecosystem, Adjustment, Power, Family, Orkla, Partnership, Accuray, PEAK, ServiceNow, AI, CO2, Video game, Beauty salon, Medical device, Pharmaceutical industry, Bank, Software, Clothing, Communications satellite, Tidal, Nuance

Total headcount at the end of the second quarter was 345,600, a decrease of 5,900 from Q1 2023 and an increase of 4,300 from Q2 2022.

Key Points: 
  • Total headcount at the end of the second quarter was 345,600, a decrease of 5,900 from Q1 2023 and an increase of 4,300 from Q2 2022.
  • The Company repurchased 3.2 million shares for $200 million during the second quarter under its share repurchase program.
  • In August 2023, the Company declared a quarterly cash dividend of $0.29 per share, a 7% increase year-over-year, for shareholders of record on August 21, 2023.
  • In addition, Cognizant will open new Google Cloud AI innovation centers in Bangalore, London and San Francisco to support a new Cognizant Google Cloud AI University to train 25,000 Cognizant associates and clients.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023
Lymphoma, Infection, Insulin resistance, Gilead Sciences, Medicaid, Medical Affairs Bureau, Depression, Partnership, Office of Inspector General, U.S. Department of Health and Human Services, Diabetes, HIV, Vaccination, Arthritis, Liver disease, Human services, Public, COVID-19, Cancer, Deficit spending, Quality of life, Hepatitis B virus, Research, Medicine, Kidney, Gilead, Liver cancer, CDC, Organization, CDA, Patient, Risk, Fibromyalgia, U.S. CDC, WHO, Liver failure, Viral hepatitis, Cirrhosis, HBV, HCV, Virus, World Health Organization, Fatigue, Pharmaceutical industry, Vaccine, Medicare, Granblue Fantasy: Relink

LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The Relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023
Health, Foundation, Philanthropy, Managed Care, Oncology, Lymphoma, Infection, Insulin resistance, Gilead Sciences, Medicaid, Medical Affairs Bureau, Depression, Partnership, Office of Inspector General, U.S. Department of Health and Human Services, Diabetes, HIV, Vaccination, Arthritis, Liver disease, Human services, Public, COVID-19, Cancer, Deficit spending, Quality of life, Hepatitis B virus, Research, Medicine, Kidney, Gilead, Liver cancer, CDC, Organization, CDA, Patient, Risk, Fibromyalgia, U.S. CDC, WHO, Liver failure, Viral hepatitis, Cirrhosis, Virus, HBV, HCV, World Health Organization, Fatigue, Pharmaceutical industry, Vaccine, Medicare

The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives

Retrieved on: 
Thursday, July 20, 2023
Amgen, Stanford University, MBA, Employment, Acquisition, Patient, Diversity, Inclusion, Principal, Compensated emancipation, Corporate development, Boston Consulting Group, Orexigen Therapeutics, Business development, University, Therapy, Arena Pharmaceuticals, American InterContinental University, Lonza, Organization development, Research, Strategic planning, Gilead, Coulter, Corporation, Knowledge, Growth, Amylin Pharmaceuticals, III, Genome, Business, Whitehead, University of Miami, Reflexive relation, Genome Research, Human, Economics, BA, Human resources, Federal Reserve Board of Governors, TAC, Pharmaceutical industry, Management, Biochemistry, Pomona College, Cain (Italian band)

Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.

Key Points: 
  • Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.
  • Mr. Williamson has successfully led multiple companies through significant growth, partnerships, financing rounds, IPOs, and successful acquisitions.
  • Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations.
  • Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute).